HiberCell
Presence
HiberCell has 7 subsidiaries including Genuity Science, WuXi Advanced Therapies and WuXi AppTec.
Executives
View the org chart displaying its 95 main executives
Most searched biographies at HiberCell
- Jonathan Lanfear, President and Chief Executive Officer
- Colin Goddard, Director
- Steven Gillis, Chairman of the Board
Create your alert
to follow the executive moves at HiberCell.
Biotechnology
HiberCell has 2,292 competitors including Eurofins (Luxembourg), Lonza (Switzerland) and Adaptive Phage Therapeutics (United States (USA)).
Popular M&A news in Biotechnology
- Lycia Therapeutics has just announced a $107 Million fundraising (posted on May 15 2024).
- Attovia Therapeutics has just announced a $150 Million fundraising (posted on May 14 2024).
- Bruker has announced the acquisition of NanoString Technologies (posted on May 13 2024).
Popular contacts in Biotechnology
News
Press releases by HiberCell
- HiberCell Announces First Patient Dosed in Clinical Collaboration with Merck, Evaluating HC-7366 in Combination with WELIREG® (belzutifan) in patients with advanced ccRCC - HiberCell
- HiberCell, Inc. Announces Clinical Collaboration with Merck to Evaluate HC-7366, an Activator of ISR Kinase GCN2, in Combination with WELIREG® (belzutifan) in a Phase 1b Study of Patients with Clear Cell Renal Cell Carcinoma (ccRCC) - HiberCell
- HiberCell Announces Successful Completion and Interim Results of Phase 1 Study of Novel PERK Inhibitor, HC-5404, in Solid Tumors and Maps Forward Path as Monotherapy and in Combinations - HiberCell
- HiberCell Doses First Patient in Phase 1b Study Exploring Novel Combination of Odetiglucan and CD40 Agonistic Monoclonal Antibody (CDX-1140) in Patients With Metastatic Pancreatic Ductal Adenocarcinoma (PDAC) in the Maintenance Setting - HiberCell
- HiberCell to Present Pre-clinical Data on its Novel GCN2 Activator and PERK Inhibitor Programs at the American Association for Cancer Research (AACR) Annual Meeting 2023 - HiberCell
- HiberCell to Present Pre-clinical Data on its Novel GCN2 Activator and PERK Inhibitor Programs at the American Association for Cancer Research (AACR) Annual Meeting 2023 - HiberCell
- HiberCell Maps Forward Path for Novel GCN2 Activator, HC-7366 in Acute Myeloid Leukemia (AML) - HiberCell
- HiberCell to Present Preclinical Data from Novel GCN2 Activator and PERK Inhibitor Programs at The Society for Immunotherapy of Cancer (SITC) 37th Annual Meeting - HiberCell
- HiberCell to Present Posters on Novel Candidates Odetiglucan and HC-7366 at the 2022 Annual American Society of Clinical Oncology Meeting - HiberCell
- HiberCell and the University of Pennsylvania Present Preclinical Anti-Metastatic Monotherapy Activity Data in Mice for Odetiglucan in Pancreatic Cancer at AACR Annual Meeting 2022 - HiberCell
- View more press releases Close
Social media about HiberCell
- HiberCell on Wikipedia, Google News & Yahoo Finance
- HiberCell on LinkedIn, Twitter & YouTube
Get in Touch
Contact by email its executives including Jonathan Lanfear 
